Researchers used computational analyses to evaluate the performance of 10 medications against the Omicron variant, finding ivermectin outperformed all of them, including nirmatrelvir (Paxlovid), a new drug from Pfizer that has cost taxpayers $5.29 billion and costs $529 per course of treatment.